
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow is a commercial-stage medical technology company with a strong and growing product portfolio, including three software products that have potential for continued development and expansion. The company operates in a large and still underpenetrated market, with a robust margin outlook and potential for both revenue upside and expansion into new markets through AI-powered software capabilities. While there are some potential risks to our target price, including competition and reimbursement changes, we maintain a positive outlook on HeartFlow's stock based on their strong Q2 results, solid business momentum, and potential for future growth and profitability.
Bears say
HeartFlow is experiencing significant growth in both its plaque and FFRCT businesses, with overall revenues beating analysts' projections and gross margins reaching a new high. The synergies between these two segments also bode well for future margin expansion. However, the company's continued increase in revenue guidance for 2026 raises concerns about potential overvaluation and the potential for future market saturation.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares